002750 Kunming Longjin Pharmaceutical
- 2.05
- -0.11-5.09%
Kunming Longjin Pharmaceutical News
Kunming Longjin Pharmaceutical: Notice of Response to the 2023 Annual Report Inquiry Letter
Kunming Longjin Pharmaceutical: 2023 Annual General Meeting of Shareholders Legal Opinions
Kunming Longjin Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Kunming Longjin Pharmaceutical: Summary report of the Board Audit Committee on the evaluation of the accounting firm's performance in 2023
Kunming Longjin Pharmaceutical: Special instructions on the proposed non-distribution of profits in 2023
Kunming Longjin Pharmaceutical: 2023 Financial Results Report
Kunming Longjin Pharmaceutical: Announcement on delisting risk warning and suspension of trading of the company's stock trading
Kunming Longjin Pharmaceutical: Internal Control Self-Assessment Report
Kunming Longjin Pharmaceutical: Notice of Annual General Meeting of Shareholders
Kunming Longjin Pharmaceutical: Notice on Accruing Asset Impairment Preparation and Credit Impairment Preparation
Longjin Pharmaceutical: An indicative announcement on the risk of delisting risk of the company's stock transactions
Longjin Pharmaceutical: Progress Announcement on Using Idle Own Funds for Cash Management
Longjin Pharmaceutical: Progress Announcement on Using Idle Own Funds for Cash Management
Longjin Pharmaceutical: Progress Announcement on Using Idle Own Funds for Cash Management
Longjin Pharmaceutical: An indicative announcement on the risk of delisting risk of the company's stock transactions
Longjin Pharmaceutical: An indicative announcement on the risk of delisting risk of the company\'s stock transactions
Longjin Pharmaceutical: Announcement on Accrued Asset Impairment Preparation and Credit Impairment Preparation
Longjin Pharmaceutical: Progress Announcement on the Use of Idle Own Funds for Cash Management
Longjin Pharmaceutical: Progress Announcement on Using Idle Own Funds for Cash Management
Longjin Pharmaceutical: Legal Opinion of the 2024 First Extraordinary General Meeting of Shareholders
Analysis
Price Target
No Data
